ARNEO: neoadjuvant degarelix + apalutamide before surgery for high-risk prostate cancer
- PMID: 36195722
- DOI: 10.1038/s41585-022-00664-4
ARNEO: neoadjuvant degarelix + apalutamide before surgery for high-risk prostate cancer
Comment on
-
ARNEO: A Randomized Phase II Trial of Neoadjuvant Degarelix with or Without Apalutamide Prior to Radical Prostatectomy for High-risk Prostate Cancer.Eur Urol. 2023 Jun;83(6):508-518. doi: 10.1016/j.eururo.2022.09.009. Epub 2022 Sep 24. Eur Urol. 2023. PMID: 36167599 Clinical Trial.
References
Original article
-
- Devos, G. et al. ARNEO: a randomized phase II trial of neoadjuvant degarelix with or without apalutamide prior to radical prostatectomy for high-risk prostate cancer. Eur. Urol. https://doi.org/10.1016/j.eururo.2022.09.009 (2022) - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
